Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on August 13, 2021. The filing serves to announce the company's financial results for the three-month period ended June 30, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1 to this report. Consequently, no specific financial metrics can be extracted from the provided text.
Material Changes
The filing does not contain a comparative analysis or specific data regarding material changes versus the prior comparable period. The document acts solely as a notification that the Q2 2021 results have been issued.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that any non-historical statements (using terms like "may," "will," "believes," "plans") are forward-looking and subject to risks.
- Risk Factors: The company directs investors to its periodic reports filed with the SEC under the heading "Risk Factors" for additional details on factors that could cause actual results to differ materially from anticipated results.
- Management Commentary: No specific management commentary or outlook is provided within the body of this 8-K text; such details are referenced as being in the attached press release.
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 13, 2021), as they are not listed in this summary text.
- Confirm the company name is AgeX Therapeutics, Inc. (Ticker: AGE), noting the discrepancy with the "Serina Therapeutics" name in the request metadata.
- Review the "Risk Factors" section in the company's most recent 10-K or 10-Q filings to understand the contingencies affecting the forward-looking statements mentioned in this report.
- Note that the information in Item 2.02 and the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.